https://proteasessignaling.com..../index.php/aggregati
In this study, we investigated the anti-leukemic outcomes of NOB on cell differentiation and its own fundamental mechanisms in man chronic myeloid leukemia (CML) K562 cells. NOB (100 μM) treatment for 24 and 48 h notably decreased viability of K562 cells to 54.4 ± 5.3% and 46.2 ± 9.9%, respectively. NOB (10-100 μM) substantially inhibited cell growth in K562 cells. Flow cytometry analysis and immunoblotting data indicated that NOB (40 and 80 μM) could modulate the cell cycle
Like
Comment
Share
